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Background: KAI1 and epithelial-mesenchymal transition (EMT) is related to both angiogenesis and
lymphangiogenesis and is an important target in new cancer treatment strategies. We aimed to investigate the
KAI1 and marker of EMT expression and correlation with lymph node metastasis (LNM) and explore their prognostic
impact in non-small cell lung cancer (NSCLC).
Methods: Tumor tissue specimens from 312 resected patients with stage I–IIIA NSCLC were obtained.
Immunohistochemistry was used to assess the expression of the molecular markers KAI1, E-cadherin (E-cad),
vimentin, CD34, and D2-40.
Results: There were 153 N0 and 159 N+ patients. Tumor cell expression of KAI1and the marker of EMT, lymphatic
vessel density (LVD), and microvessel density (MVD) were related to LNM. In multivariate analyses, the ages of
patients, high tumor cell KAI1 expression, EMT, and the scores of MVD were independent factor of prognosis.
Conclusions: Tumor cell KAI1 expression, EMT, LVD, and MVD correlate with LNM. Thus, the detection of KAI1,
expression of markers of EMT, and the scores of MVD may be used as a potential indicator of NSCLC prognosis.
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Lung cancer is the most frequent malignancy and the first
leading cause of cancer-related death worldwide [1].
Complete surgical resection is the only potential curative
treatment for localized lung cancer. About 65 % non-small
cell lung cancer (NSCLC) patients who are suitable for sur-
gical procedures will relapse within 2 years and subse-
quently die of metastatic spread [2, 3]. A common feature
of tetraspanins is regulating cell motility. The mechanism
that tetraspanins modulate cell motility is still unclear.
KAI1 gene was originally identified as a suppressor of
metastasis of tumor in prostate cancer and located on
human chromosome 11p11.2 [4]. It is a member of the tet-
raspanins superfamily of glycoproteins. KAI1 suppresses
metastasis by multiple mechanisms regulating inhibition of
cell motility, adhesion, fusion, and proliferation [5]. It was* Correspondence: 573448542@qq.com
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membrane structure by interactions with cell surface mole-
cules, such as cell adhesion molecules and other tetraspa-
nins. Many studies have shown that decreased KAI1
expression could be a useful marker for metastatic, invasive,
and prognostic factor in many human tumors, such as lung
[6], breast [7, 8], gastric [9, 10], liver [11], colorectal [12],
bladder[13], esophageal [14], and prostatic cancer [15].
Epithelial-mesenchymal transition (EMT) is a reversible
embryonic process and aberrantly activated in tumor pro-
gression and metastasis. Many studies have shown that
EMT was a critical process in tumor invasion and metasta-
sis in NSCLC [16, 17]. It is commonly characterized by
downregulation of E-cadherin (E-cad) which is a critical cell
to cell adhesion molecule [18] and upregulation of vimentin
which plays an important role in cell migration [19]. KAI1
may stabilize or strengthen E-cad-dependent cell-to-cell ad-
hesion and motility by regulating β-catenin-mediated signal
transduction on tumor cells, thus preventing tumor cells
from seceding from the primary tumor [20]. These effectsicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Zhou et al. World Journal of Surgical Oncology  (2015) 13:234 Page 2 of 8suggest that KAI1-induced E-cad signaling provides a sur-
vival benefit for metastatic tumors; however, whether KAI1
can inhibit EMT in NSCLC cells and the mechanism in-
volved remains unclear.Methods
Patients and clinical samples
Primary tumor tissues diagnosed NSCLC with pathologic
stage I–IIIA from patients at the First Hospital Affiliated
of Bengbu Medical College from 2003 to 2007 were used
in this retrospective study. In total, 365 patients were
registered from the hospital database. Of these, 53 patients
were excluded from the study due to the following: (i)
radiotherapy or chemotherapy before surgery (n = 15), (ii)
other malignancy within 5 years before NSCLC diagnosis
(n = 17), and (iii) inadequate paraffin-embedded fixed
tissue blocks (n = 20). Thus, 312 patients with complete
medical records and adequate paraffin-embedded tissue
blocks were eligible. Due to financial or other reasons, 265
(84.9 %) patients were to postoperative therapy (postoper-
ative routine chemotherapy or radiotherapy).
This report includes follow-up data as of 31 October
2012. The median follow-up was 42 (range 8–105)
months. All specimens were obtained from the archives of
the Department of Pathology at our hospital. The tumors
were graded according to the World Health OrganizationFig. 1 Representative results of KAI1 and vimentin and E-cadherin protein in
predominantly localized in the membrane and cytoplasm in well-differentiate
of E-cadherin protein. d Vimentin protein localized in the cytoplasm and memand staged according to the International Union Against
Cancer’s tumor-node-metastasis classification. This study
was approved by the ethical committee of Bengbu Medical
College before it started.Immunohistochemistry
All applied antibodies were subjected for immunohisto-
chemistry (IHC) analysis on paraffin-embedded tissue.
The antibodies used in this study were as follows: KAI1
(mouse monoclonal; Santa Cruz), E-cad (mouse monoclo-
nal; LabVision), vimentin (mouse monoclonal; LabVision),
CD34 (mouse monoclonal; LabVision), and D2-40 (mouse
monoclonal; LabVision). The IHC procedures for these
markers were previously described [21]. For each anti-
body, including negative controls, IHC was done in a
single experiment.Scoring of IHC
By light microscopy, representative tissue sections were
scored semiquantitatively for cytoplasmic and membrane
staining. All samples were anonymized and independently
observed by two pathologists. If there is a disagreement, the
observers would reexamine and reach a consensus. In scor-
ing expression of antibodies, both the intensity and extent
of immunopositivity were considered. The dominant stain-
ing intensity in tumors was scored as follows: 0 = negative,NSCLC. a Moderately differentiated NSCLC, H&E staining. b KAI1 protein
d squamous carcinoma. c NSCLC cells did not express a detectable level
brane in NSCLC cells (a, c, and d are serial sections)
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positive staining tumor cells was scored as follows: <10 % is
1, 11–50 % is 2, 51–75 % is 3, and >75 % is 4. The final
score was determined by multiplying the intensity and the
extent positivity scores, which yielded a range from 0 to 12.
Mean score from each individual was calculated in tumor
cells. The positive expression for markers was scored as
follows: >2, KAI1; >3, E-cadherin; and >1, vimentin.
The positive expression of KAI1 and E-cad was found
mainly on the membrane and cytoplasm of NSCLC
cells and normal lung tissues. The positive expression
of vimentin was found mainly on the cytoplasm of
NSCLC cells and normal lung tissues. They were pre-






<60 95 52 88
≥60 111 54 100
Gender 0.038
Male 147 87 138
Female 59 19 50
Diameter 0.081
<3.0 cm 32 9 30
≥3.0 cm 174 97 158
Histology 0.283
SCC 155 79 144
Adenocarcinoma 43 26 36
LCC 8 1 8
Smoking 0.957
Yes 151 78 139
No 55 28 49
Grades of tumor <0.001
Well 10 31 13
Moderately 135 68 116
Poorly 61 7 59
TNM stages <0.001
I 10 57 7
II 85 35 77
III 111 14 104
VI <0.001
Yes 42 1 40
No 164 105 148
Marginal free 0.119
Yes 171 95 155
No 35 11 33
NSCLC non-small cell lung cancer, SCC squamous cell carcinoma, LCC large cell carcMicrovessel and lymphatic vessel density
We assessed lymphatic vessel density (LVD) by D2-40
and microvessel density (MVD) by CD34 immunohisto-
chemical staining. Not only stained endothelial cell but
also endothelial cell cluster separated from other stromal
elements was considered as a countable microvessel or
lymphatic vessel.
Statistical methods
All statistical analyses were done using the statistical
software SPSS (SPSS inc., Chicago, IL), version 17. The
Fisher’s exact test and Pearson chi-square test for
trends in proportions, Spearman’s correlate analysis,



































inoma, VI vascular invasion
Table 2 KAI1 and EMT and vascular endothelial and lymphatic endothelial marker as predictors for lymph node metastasis in 312
NSCLC patients (X2)




P(X2) N0 + N1
Verse N2
KAI1 <0.001 <0.001 <0.001
Negative 206 84 80 42
Positive 106 69 34 3
Co-expression <0.001 <0.001 <0.001
Low V/high E 114 75 36 3
Low V/low E 66 29 33 4
High V/high E 10 5 2 3
High V/low E 122 44 43 35
MVD score <0.001 <0.001 <0.001
Mean 21.6 ± 12.0 18.0 ± 11.5 23.4 ± 11.0 29.2 ± 11.2
LVD score <0.001 0.005 <0.001
Mean 4.8 ± 2.8 4.4 ± 2.7 4.9 ± 2.7 6.2 ± 2.5
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disease-specific survival (DSS) analysis were used to
assess the associations among the positive staining of
KAI1, E-cad, vimentin, LVD, or MVD and clinicopatho-
logical indices. DSS was defined from the date of sur-
gery to the time of NSCLC death. A value of P < 0.05
was considered statistically significant.
Results
The relationship between expression of KAI1, E-cad, and
vimentin and clinicopathological parameters
In NSCLC (Fig. 1b), the positive expression of KAI1 was
34.0 % (106/312) (Fig. 1a), the positive expression of E-cadFig. 2 Disease-specific survival curves according to NSCLC cells expression
in the negative expression of KAI1 group was 34.6 months, compared with
with N+ status (n = 159), the median survival in the negative expression of
positive expression of KAI1 groupwas 39.7 % (124/312) (Fig. 1c), and the positive expression
of vimentin was 42.3 %(132/312) (Fig. 1d). There was a
significant difference between the expression of KAI1, E-
cad, and vimentin and grades of tumors (P < 0.001) and
TNM stage (P < 0.001) (Table 1).Expression of KAI1 and LNM and DSS (Table 2)
The negative expression of KAI1 was seen significantly
(P < 0.001) more often in N+ (50.5 %) than N0 when
compared with positive expression of KAI1 (45.1 %).
The negative expression of KAI1 was seen signifi-
cantly (P < 0.001) more frequent in N2 (14.4 %) than inof KAI1. a In the total cohort of patients (n = 312), the median survival
67.3 months in the positive expression of KAI1 group. b In all patients
KAI1 group was 32.0 months, compared with 79.2 months in the
Fig. 3 Disease-specific survival curves according to NSCLC cells co-expression of vimentin and E-cad. a In the total cohort of patients (n = 312),
the median survival in the low E-cad/high vimentin group was 28.8 months, compared with 66.0 months in the high E-cad/low vimentin group
and 43.3 months in the low E-cad/low vimentin group. b In all patients with N+ status (n = 159), the median survival in the low E-cad/high
vimentin group was 48.4 months, compared with 69.1 months in the high E-cad/low vimentin group and 27.4 months in the low
E-cad/low vimentin
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KAI1 (38.6 %).
In univariate analyses, the negative expression of KAI1
was clearly associated with poor survival (P < 0.001) as
shown in Fig. 2a.
In the N+ (N1 +N2) patient cohort (159 patients), the
negative expression of KAI1 group (n = 122) was related
with a significantly worse prognosis (P < 0.001) when com-
pared with the positive expression of KAI1 group (Fig. 2b).Fig. 4 Disease-specific survival curves according to NSCLC of MVD. a In the
group was 57.1 months, compared with 31.7 months in the MVD≥ 22 grou
MVD <22 group was 52.4 months, compared with 31.8 months in the MVD ≥Co-expression of E-cad/vimentin and LNM (Table 2)
Low E-cad/high vimentin expression was seen signifi-
cantly (P < 0.001) more often in N+ than N0 when
compared with high E-cad/high vimentin (3.3 %), high
E-cad/low vimentin (49.0 %), or low E-cad/low vimen-
tin (19.0 %).
Low E-cad/high vimentin expression was seen signifi-
cantly (P < 0.001) more frequent in N2 than in N0 + N1
when compared with high E-cad/high vimentin (2.6 %),total cohort of patients (n = 312), the median survival in the MVD <22
p. b In all patients with N+ status (n = 159), the median survival in the
22 group (MVD ≥22, because the mean score of MVD was 21.6 ± 12.0)
Fig. 5 Disease-specific survival curves according to NSCLC of LVD. a In the total cohort of patients (n = 312), the median survival in the LVD <5
group was 54.5 months, compared with 34.0 months in the LVD ≥5 group. b In all patients with N+ status (n = 159), the median survival in the
LVD <5 group was 53.7 months, compared with 29.4 months in the LVD ≥5 group (LVD ≥5, because the mean score of LVD was 4.8 ± 2.8)
Table 3 Multivariate survival analysis of 312 patients with
NSCLC
Covariate B SE Sig Exp(B) 95 % CI
Age −0.239 0.118 0.044 0.788 0.625–0.993
TNM stages 0.311 0.21 0.010 1.365 1.078–1.730
KAI1 −1.495 0.199 <0.001 0.224 0.152–0.332
MVD score 0.326 0.162 0.044 1.385 1.009–1.901
Marginal 1.091 0.176 <0.001 2.978 2.110–4.203
Co-expression 0.633 0.074 <0.001 1.882 1.628–2.176
Therapy −0.551 0.170 0.001 0.576 0.413–0.804
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vimentin (23.2 %).
Co-expression of E-cad/vimentin and DSS
In univariate analyses, the co-expression of low E-cad/
high vimentin was clearly related with poor survival
(P < 0.001) as shown in Fig. 3a.
In the N+ (N1 +N2) patient cohort (159 patients), the
low E-cad/high vimentin expression group (n = 78) had a
median survival of 26.7 months and was related with a
significantly worse prognosis (P < 0.001) when compared
with low E-cad/low vimentin and high E-cad/low vimen-
tin expression group (Fig. 3b).
LVD and MVD and LNM and DSS (Table 2)
High scores of LVD (5.2 ± 2.7) and MVD (25.0 ± 11.4)
were seen significantly (P < 0.01) more often in N+ than
N0 when compared with low scores of LVD (4.4 ± 2.7)
and MVD (18.0 ± 11.5).
High scores of LVD (6.2 ± 2.5) and MVD (29.2 ± 11.2)
were seen significantly (P < 0.001) more frequent in N2
than N0 +N1 when compared with low scores of LVD
(4.6 ± 2.7) and MVD (20.3 ± 11.6).
In univariate analyses, the MVD ≥22 group or LVD ≥5
group was clearly associated with poor survival (P < 0.001)
as shown in Fig. 4a or in Fig. 5a.
In the N+ (N1 +N2) patient cohort (159 patients), the
MVD ≥22 group (n = 92) or LVD ≥5 group (n = 84) was
related with a significantly worse prognosis (P < 0.001)
when compared with the MVD <22 group (n = 67) or
LVD <5 group (n = 75) (Fig. 4b or Fig. 5b).
In the multivariate Cox regression analysis, includ-
ing all significantly clinicopathological parameters(Table 1) and the co-expression E-cad/vimentin and
the scores of LVD and MVD, the co-expression of E-
cad/vimentin, the expression of KAI1, the score of
MVD, pTNM stages, age of patients, marginal, and
therapy emerged as independent prognostic factors for
DSS (Table 3).Discussion
In this study, we analyze 312 samples of surgically
resected NSCLC Chinese patients using immunohisto-
chemical method. We found that tumor cells expressed
KAI1, E-cadherin, and vimentin protein to be independ-
ently associated with nodal metastasis and the co-
expression of E-cadherin and vimentin and expression of
KAI1 in tumor cells to be significantly associated with
NSCLC patient prognosis.
To identify the relationship between KAI1 and EMT
in NSCLC, five frequent indicator markers were de-
tected in NSCLC tissues using IHC method. Many
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regulate E-cad-dependent cellular adhesion in many tu-
mors. In this study, we found that KAI1 protein expres-
sion was decreased in NSCLC and was correlated with
grade of tumors and a poor prognosis, and so was E-
cad. There was a positive relationship between the ex-
pression of KAI1 and E-cad. The low expression of
KAI1 and E-cad lost their function which inhibited
tumor cells invasion. In vivo data suggested that KAI1
be involved in EMT of NSCLC. We also found that
there was a negative correlation between KAI1 and
vimentin. These indicated that there was a potential
role of KAI1 in EMT of NSCLC. However, to our
knowledge, there was no study available on the associ-
ation between the expression of KAI1 and EMT. The
mechanism might have been the hypothesis as follows:
Cell adhesion and motility, the functions of E-cad, were
commonly regulated by β-catenin which forms E-cad-
β-catenin complexes. KAI1 could inhibit β-catenin
tyrosine phosphorylation and stabilize E-cad-β-catenin
complexes and thus prevent tumor cells dissemination
from primary tumors [20]. The protein tyrosine kinase
Src had been reported to be potent induces of EMT
[25]. KAI1 expression could inhibit activation of Src
kinase in the process of tumor malignancy and angio-
genesis [26–28].
EMT has been found to be critical in tumor dissemin-
ation, local invasion, and metastasis, endowing cells with
cancer stem cell properties [29–31]. Its common charac-
teristic is downregulation of E-cad expression and upregu-
lation of vimentin expression; this leads to numerous
phenotypic changes such as the loss of cellular adhesion
and polarity and the acquisition of migratory and invasive
phenotype [32]. In this study, we have found strong diffuse
expression of vimentin by immunohistochemistry and
concomitant loss of E-cad expression in the majority of
poorly differentiated NSCLC but not in normal lung tissue
and well-differentiated NSCLC. We have found that the
level of co-expression of E-cad/vimentin was associated
with lymph node metastasis (LNM) and poor pathological
TNM stages and poor clinical survival. This could be
explained by the frequency invasive subpopulations of
tumor cells resulting from EMT. Decreased E-cad and
increased vimentin expression in LNM correlated with a
shorter DSS. Many studies have shown that EMT
phenomenon indicated a short survival in many human
tumors [16, 17, 33–39]. But some authors did not believe
that vimentin was associated with survival in NSCLC [16].
We observed a correlation of KAI1 and E-cad protein
downregulation with vessel infiltration and metastasis in
NSCLC. In contrast, vimentin protein is upregulated in
NSCLC. These indicated that KAI1 and EMT should be
involved in tumor cell invasion and metastasis. On the
whole sections, we found that the strong KAI1 and E-cadherin expression of tumor cells was far from stromal
cells. Upregulation expression of vimentin in tumor cells
was often close to and inside intratumoral vessels. At the
same time, the level of KAI1 and E-cad expression, less
than normal lung tissues, was associated with low or
absent vimentin expression in the majority of well or
moderately differentiated tumors. But in poorly differenti-
ated tumors, weak and absent E-cad expression was asso-
ciated with the predominated expression of cytoplasmic
vimentin. This study also found that high expression of
KAI1 and E-cad could inhibit tumor angiogenesis and
lymphangiogenesis. Increased vimentin expression could
promote tumor angiogenesis and lymphangiogenesis.
KAI1 inhibited β-catenin tyrosine phosphorylation, and
this would stabilize the E-cad functions [20]. These find-
ings might indicate that KAI1 functions as a metastasis
suppressor in the process of tumor invasion, angiogenesis,
and lymphangiogenesis through inhibition of β-catenin-
mediated EMT.
Conclusions
It is suggested that KAI1 may play an important role in
the LNM of NSCLC. Our results also show that KAI1
and EMT may be possible as a therapeutic marker for
anti-metastasis therapy.
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